Healthcare Industry News: Actimab-A
News Release - February 21, 2017
Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial StrategyIndustry veteran to lead development of optimized programs for Iomab-B including initiatives targeted at patients, physicians and payors designed to support clinical development and pre-commercialization efforts
Mr. Price brings three decades of marketing and strategic leadership experience in the oncology field with most recent experiences in immunotherapy focused on hematology at Merck and antibody-based therapeutics at Imclone Systems
NEW YORK, Feb. 21, 2017 -- (Healthcare Sales & Marketing Network) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that Steven Price has been appointed to the newly created position of Vice President, Clinical and Commercial Strategy. In this role, Steve will initially focus on pre-commercial efforts including strategic planning and product messaging for Iomab-B, increasing awareness for Iomab-B, further developing relationships with the physician community, and supporting clinical trials for Actinium’s current and future clinical programs. He will also be in charge of pre-commercial activities for Actimab-A and Actimab-M.
“I am incredibly honored to join Actinium at this point in the Company’s evolution and excited to be working with a strong and committed team”, said Steve Price. “The data to date for Iomab-B and Actimab-A are very impressive and suggest these drug candidates have the potential to improve patient outcomes in disease indications with high unmet needs. I look forward to leveraging my experience and relationships to further enhance the profiles of Actinium’s drug candidates to the hematology and bone marrow transplant community while positioning them for future success.”
Most recently, Steve was at Merck as Global Disease Lead, Hematology where he focused on Keytruda, an anti-PD-1 immuno-oncology antibody. In this position, Steve served as commercial lead on the product development team responsible for maximizing physician acceptance, KOL development, market penetration and new indication launch uptake. Further, he developed the marketing program ahead of product launch before implementing at the regional level and guiding regional teams in a new indication launch. Prior to Merck, Steve consulted to pharmaceutical and biotechnology companies on product pre-launch strategies, pre-market evaluations, developing and implementing marketing strategies, and KOL development. Previously, Steve worked at Imclone Systems, now a wholly owned subsidiary of Eli Lilly, as Associate Vice President, Global New Products Strategic Marketing. At Imclone, Steve was the commercial lead for 10 antibody therapeutics where he was responsible for all commercial aspects of the New Product Pipeline. In addition, Steve was Vice-chair of the Hematology council where he reviewed assets and advised on the development of new compounds. Steve has also worked as National Director of Sales and Marketing at Enzon Corporation and as Marketing Director at Immunex Corporation until it was acquired by AMGEN.
Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals said, “Steve’s hiring represents another significant step in Actinium’s growth and one that I am most excited about. Steve brings to Actinium a significant amount of knowledge and experience specific to hematology and also has deep relationships that he curated in his 30 years in this field. I look forward to working with Steve and the rest of the Actinium team in building a great company that is focused on improving outcomes for patients.”
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company's second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceuticals is based in New York, NY. To learn more about Actinium Pharmaceuticals, please visit www.actiniumpharma.com and to follow @ActiniumPharma on Twitter please visit, www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Source: Actinium Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.